What happened with WGS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
GeneDx Holdings Corp. helps healthcare professionals find genetic explanations for patients’ conditions, particularly pediatric and rare diseases. It reads either the protein-coding regions of DNA, called the exome, or the whole genome, then interprets the findings and delivers a diagnostic report. Its specialists use the GeneDx Infinity rare-disease dataset alongside software and AI tools to interpret genetic findings.
Diagnostic testing brings in nearly all revenue, and most test revenue comes from orders for patients with third-party insurance. Insurers and other healthcare payors, institutional clients and patients pay GeneDx for testing. Hospitals and other institutions also buy its services directly; data and information services are a smaller business.
The business depends on clinicians ordering tests and payors agreeing to cover them at adequate rates. Payors can deny claims or reclaim earlier payments. GeneDx also relies on a small group of laboratory suppliers, including Illumina, and has not validated a commercially viable alternative sequencing platform. Its laboratories must maintain CLIA certification and applicable licenses to operate and qualify for payment from many payors, while health-data privacy rules restrict how it can use and disclose patient information.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
GeneDx’s results hinge on rare-disease exome and genome test volumes and reimbursement; watch Baylor Genetics and Variantyx, important competitors missing from this list.
Tempus AI, through Ambry Genetics, competes for healthcare providers’ hereditary genetic-testing orders that could otherwise go to GeneDx. Watch its hereditary-testing business rather than its oncology tests or data sales for signs of pressure on GeneDx.
Fulgent Genetics competes with GeneDx for genetic-testing orders through its precision-diagnostics laboratory business, earning revenue from tests and physicians’ interpretation of results. Watch its new tests and cost per test: Fulgent says its technology supports a broader test menu and lower testing costs.
GeneDx depends on Illumina’s sequencing equipment and consumables to run diagnostic tests, while also naming Illumina as a competitor in genetic tools and services. Supply disruptions matter because switching suppliers can interrupt GeneDx’s laboratory workflow and require tests to be validated again.
Labcorp competes with GeneDx for clinical genetic-testing orders, including through the Invitae assets it acquired. Those tests are only a small part of Labcorp’s broader business, so its overall results are a less direct guide to the competitive pressure on GeneDx.
GeneDx relies on laboratory equipment or materials supplied by Agilent Technologies, so replacing that supply can disrupt testing and require tests to be validated again. Agilent sells laboratories instruments, consumables, software and services; continuity of the supplies GeneDx uses matters more here than Agilent’s overall sales.
GeneDx Holdings Corp. earningsThis company
GeneDx recognizes revenue when it delivers test results, so this report will show whether growth in exome and genome testing is holding up reimbursement and profit per test.
Read completed exome and genome tests alongside average reimbursement and gross profit. More tests with reimbursement and gross profit holding up would show that added orders are becoming revenue without costs consuming the gains. Flat or falling test volume, or weaker reimbursement and gross profit, would point to demand, payer rates or testing costs offsetting growth. The conclusion is whether GeneDx can turn more tests into stronger-quality revenue.
Illumina Inc earningsILMN
Illumina supplies sequencing equipment and consumables GeneDx relies on, so its report can offer clues about supply and cost pressures along GeneDx's testing path.
Watch Illumina's comments on demand for sequencing equipment and consumables, and any disclosed supply or cost changes, against GeneDx's reliance on those inputs to run tests. Stable supply and easing cost pressure would mean less risk of disruption to GeneDx's testing workflow. Shortages or rising costs would raise the risk of delays, higher test costs or time-consuming validation of alternatives. Illumina's overall results cannot confirm GeneDx's own supply position, so the conclusion is whether the external risk signal has strengthened or eased—not that a disruption has occurred.
Tempus AI, Inc. earningsTEM
Tempus AI competes through Ambry Genetics for hereditary-testing orders from healthcare providers, so its report can show whether competition is intensifying for orders that may otherwise go to GeneDx.
If the report breaks out hereditary testing, compare changes in that business's orders or revenue with the direction of Tempus AI's other testing activity. Faster growth in hereditary testing would show stronger momentum for Tempus AI in provider orders that may also go to GeneDx, raising the competitive pressure signal. Weak hereditary-testing activity while other business grows would point to pressure concentrated elsewhere and a weaker signal from this channel. The companies' test mixes differ, so this indicates a change in the competitive setting, not proof that GeneDx won or lost orders.
